New research is advancing understanding of certain cancers and complex congenital disorders by illuminating how BRD4, a protein that scientists have studied for years, directs the spatial ...

Numerous disease development processes are linked to epigenetic modulation. One protein involved in the process of modulation and identified as an important cancer marker is BRD4. A recent study ...

On September 12, 2023, a new research paper was published in Genes & Cancer, entitled, “Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in ...

Recently, BRD4 has emerged as a potential target for cancer therapy due to its role as an epigenetic and transcriptional regulator of the cell cycle. 1–5 Specifically, several hematopoietic ...

A new study, published in JCI insight, looks at how Brd4, a regulator of the innate immune response, influences diet-induced obesity. The researchers believe that Brd4 could be used as a target ...

DeepCure to Present First Ex Vivo Rheumatoid Arthritis Patient Data for Selective BRD4 (BD2) Inhibitor DC-9476 at ACR Convergence 2024 October 24, 2024 08:00 AM Eastern Daylight Time ...

BRD4, a member of the BET protein family, plays a critical role in cancer progression by regulating oncogenes, particularly MYC, which drives tumor growth but is difficult to target directly.

Epigenetic drugs that have shown promise in cancer trials significantly reduce scarring in the cells of patients with scleroderma, a new study shows. Results reveal that drugs that inhibit BRD4 ...

“Our selective BRD4 (BD2) inhibitor, DC-9476, demonstrates a potentially new strategy to treat MAS by directly inhibiting macrophage activation,” said Kfir Schreiber, CEO & Co-Founder of DeepCure.

Simcere Zaiming Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon E3 ubiquitin ligase binding moiety coupled to a probable global ...